BioSpace News Archive

Job Trends

BioSpace Movers and Shakers: April 19

Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

April 18, 2019
·
5 min read
·
Alex Keown
Deals

Ipsen Completes Acquisition of Clementia Pharmaceuticals

Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients

April 18, 2019
·
8 min read
Business

Sartorius Starts off Fiscal 2019 with a Strong First Quarter

Group revenue up 16.8%; order intake up 16.6%; earnings margin1) 26.2%

April 18, 2019
·
9 min read
Policy

China based innovation, CDMOs and Parallel Approvals driving huge growth in manufacturing at CPhI China - April 18, 2019

Significant increase in exhibitors driven by bio growth at bioLIVE and separate nutraceuticals event.

April 18, 2019
·
5 min read
Business

NetCents Technology Begins Processing for First Charity Partner: HS Aware

NetCents Technology Inc. is pleased to announce that it has begun processing cryptocurrency transactions for its first charity partner, HS Aware.

April 18, 2019
·
4 min read
Deals

Sobi™ Publishes 2018 Annual and Sustainability Report

Swedish Orphan Biovitrum AB has released the company’s 2018 Annual and Sustainability Report.

April 18, 2019
·
2 min read
Deals

Walgreens Boots Alliance Declares Regular Quarterly Dividend of 44 cents per share

Walgreens Boots Alliance, Inc. announced that its board of directors has declared a regular quarterly dividend of 44 cents per share, unchanged from the previous quarter and an increase of 10 percent over the year-ago quarter.

April 18, 2019
·
3 min read
Pharm Country

Cognizant Named Top Healthcare Service Provider in New HFS Report

Research Firm’s Top Ten Report Recognizes Cognizant for ‘Simplifying Healthcare’

April 18, 2019
·
2 min read
Business

Danaher Reports First Quarter 2019 Results

Danaher Corporation announced results for the first quarter 2019.

April 18, 2019
·
22 min read
Genetown

Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development

Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies in high-need indications

April 18, 2019
·
6 min read